Corrigendum to The role of novel anticoagulants in the management of venous thromboembolism

Abstract

The authors (Nedaa Skeik, Caleb J Murphy and Brandon R Porten) would like to highlight the following corrections to Table 2 in their review article, DOI: 10.1177/1358863X14534309. The review was printed in Vascular Medicine 2014; 19: 205–214. The authors would like to apologize for any inconvenience these changes will cause.

In Table 2, next to “Prophylaxis for THR vs. Enoxaparin”, under “Apixaban” it should read “ ADVANCE 3. superior” basically removing number 2.

In Table 2, next to “Evidence for VTE Prophylaxis for TKR vs. Enoxaparin” under “Apixaban” it should read “Lassen et al. (2007), ADVANCE 2. Superior “.

Please see corrected Table 2 below.

Table 2.

Novel Anticoagulant: Indications, dosages, and evidence.

	Dabigatran	Rivaroxaban	Apixaban
FDA Approved Indications	NVAF	- NVAF	- NVAF
		- VTE prophylaxis with THR/TKR
		- VTE treatment
		- VTE secondary prophylaxis
Approved Dosages	- 150 mg BID (CrCl; >50mL/min)	NVAF:	- 5.0 mg BID
	- 75 mg BID (CrCl: 15-30mL/min)	- 20 mg daily (CrCl >50 mL/min)	- 2.5 mg BID:
	- 110 mg BID (Europe only)	-15 mg daily (CrCl 15-50 mL/min)	If at least 2 of:
		VTE prophylaxis with THR/TKR:	• Age>80
		- 10 mg daily for 35 days (THR)	• Cr>1.5mL/min
		- 10 mg daily for 12 days (TKR)	• Weight<60kg
		Treatment of acute VTE:
		- 15 mg BID for 3 weeks then 20 mg daily
		VTE risk reduction:
		- 20 mg daily
Evidence for NVAF	RE-LY	ROCKET-AF	ARISTOTLE
vs. warfarin	Superior (ischemic stroke)	Non-inferior (ischemic stroke)	Superior (all stroke)
Evidence for VTE Prophylaxis for THR vs. Enoxaparin	RE-NOVATE I and II	RECORD 1 and 2	ADVANCE 3
	non-inferior	superior	superior
Evidence for VTE Prophylaxis for TKR vs. Enoxaparin	RE-MODEL/RE-MOBILIZE	RECORD 3 & 4	Lassen et al. (2007)
	non-inferior	superior	ADVANCE 2
			superior
Evidence for VTE Prophylaxis in Medical Inpatients vs. Enoxaparin	-	MAGELLAN	ADOPT
		non-inferior at 10 days	More major bleed with apixaban without superiority in efficacy
		Superior at 35 days follow up
Evidence for VTE Management vs. LMWH/VKA	RE-COVER	EINSTEIN	AMPLIFY
	non-inferior	non-inferior	non-inferior
Evidence for VTE risk reduction after initial treatment	- RE-MEDY: Non-inferior vs. warfarin	EINSTEIN EXT	AMPLIFY-EXT
	- RE-RONATE: superior vs. placebo	Superior vs. placebo	Superior vs. placebo

NVAF: non-valvular atrial fibrillation, VTE: venous thromboembolism, THR: total hip replacement, TKR: total knee replacement, CrCl: creatinine clearance, LMWH: low molecular weight heparin, and VKA: vitamin K antagonist.

Grey highlights indicate the corrected text.